AI-powered breakthrough could revolutionise drug development
A new AI model from biotech firm Iambic Therapeutics could revolutionise drug development, potentially cutting costs in half by identifying effective drugs early in the testing process.
Nvidia-backed biotech firm Iambic Therapeutics has introduced Enchant, an AI model that aims to reduce the time and cost of drug development. Enchant, trained on extensive pre-clinical data, is designed to predict a drug’s early performance with impressive accuracy. In Iambic’s studies, Enchant achieved a 0.74 accuracy score in predicting drug absorption in the human body, compared to previous models which peaked at 0.58. This predictive power could help pharmaceutical companies identify promising drugs sooner, significantly cutting down on failed late-stage trials.
According to Iambic’s co-founder Fred Manby, Enchant could potentially slash development costs by half, as researchers could more accurately assess a drug’s success at the earliest stages. Nobel laureate and Iambic board member Frances Arnold also highlighted Enchant’s unique capabilities, noting that unlike models like Google DeepMind’s AlphaFold, which focus on molecular structure, Enchant evaluates pharmacokinetic and toxicity properties crucial to drug success.
With Enchant, Iambic is poised to set a new standard in the pharmaceutical industry by addressing some of the biggest hurdles in drug development, including high costs and late-stage failures. The AI technology’s rollout could mark a major shift, making drug discovery both faster and more efficient for a variety of treatments.
